Advertisement

Lidocaine Injection

[09 September 2016]

Products Affected - Description

Xylocaine injection, Fresenius Kabi
1%, 20 mL vial, 25 count (NDC 63323-0485-27)
1%, 50 mL vial, 25 count (NDC 63323-0485-57)
2%, 20 mL vial, 25 count (NDC 63323-0486-27)
2%, 50 mL vial, 25 count (NDC 63323-0486-57)
 
Lidocaine Hydrochloride injection, AuroMedics
1%, 2 mL vial, 10 count (NDC 55150-0161-02)
2%, 2 mL vial, 10 count (NDC 55150-0164-02)
2%, 5 mL vial, 10 count (NDC 55150-0165-05)
 
Lidocaine Hydrochloride injection, Fresenius Kabi
1%, 2 mL vial, 25 count (NDC 63323-0201-02)
1%, 10 mL vial, 25 count (NDC 63323-0201-10)
2%, 2 mL vial, 25 count (NDC 63323-0202-02)
2%, 5 mL Tear-top preservative-free vial, 25 count (NDC 63323-0208-05)
 
Lidocaine Hydrochloride injection, Hospira
1%, 30 mL sterile-pack preservative-free vial, 25 count (NDC 00409-4270-01)
1.5%, 20 mL sterile-pack, preservative-free, glass ampule, 5 count (NDC 00409-4056-01) - discontinued
2%, 50 mL vial, 25 count (NDC 00409-4277-02)

Reason for the Shortage

  • Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
  • AuroMedics introduced lidocaine injection in February 2014.
  • Fresenius Kabi has generic lidocaine presentations on shortage due to a supply interruption of API. Xylocaine products are not affected.
  • Hospira has lidocaine presentations on shortage due to manufacturing delays and increased demand.

Available Products

Xylocaine injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0484-57)
2%, 10 mL vial, 25 count (NDC 63323-0486-17)
Xylocaine-MPF injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0491-57)
1%, 2 mL vial, 25 count (NDC 63323-0492-27)
1%, 5 mL vial, 25 count (NDC 63323-0492-57)
1%, 30 mL sterile-pack vial, 5 count (NDC 63323-0492-31)
1%, 30 mL vial, 25 count (NDC 63323-0492-37)
1.5%, 10 mL ampule, 5 count (NDC 63323-0493-97)
1.5%, 20 mL ampule, 5 count (NDC 63323-0493-91)
2%, 2 mL vial, 25 count (NDC 63323-0495-27)
2%, 5 mL vial, 25 count (NDC 63323-0495-07)
2%, 10 mL ampule, 5 count (NDC 63323-0496-97)
 
Lidocaine Hydrochloride injection, Amphastar
2%, 5 mL Luer-Jet Emergency syringe, 10 count (NDC 76329-3390-01)
 
Lidocaine Hydrochloride injection, AuroMedics
1%, 2 mL ampule, 10 count (NDC 55150-0158-72)
1%, 5 mL ampule, 10 count (NDC 55150-0159-74)
1%, 5 mL vial, 10 count (NDC 55150-0162-05)
1%, 30 mL vial, 1 count (NDC 55150-0163-30)
2%, 2 mL ampule, 10 count (NDC 55150-0160-72)
 
Lidocaine Hydrochloride injection, Hospira
0.5%, 50 mL SD Tear Top preservative-free vial, 25 count (NDC 00409-4278-01)
0.5%, 50 mL SD Flip Top vial, 25 count (NDC 00409-4275-01)
1%, 2 mL preservative-free glass ampule, 50 count (NDC 00409-4713-32)
1%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-9137-05)
1%, 5 mL LifeShield syringe, 10 count (NDC 00409-4904-34)
1%, 5 mL preservative-free glass ampule, 50 count (NDC 00409-4713-02)
1%, 20 mL vial, 25 count (NDC 00409-4276-01)
1%, 30 mL preservative-free vial, 25 count (NDC 00409-4279-02)
1%, 50 mL vial, 25 count (NDC 00409-4276-02)
1.5%, 20 mL preservative-free ampule, 25 count (NDC 00409-4776-01)
2%, 2 mL preservative-free glass ampule, 25 count (NDC 00409-4282-01)
2%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-1323-05)
2%, 5 mL LifeShield syringe, 10 count (NDC 00409-4903-34)
2%, 5 mL preservative-free vial, 10 count (NDC 00409-2066-05)
2%, 10 mL preservative-free glass ampule, 25 count (NDC 00409-4282-02)
2%, 20 mL vial, 25 count (NDC 00409-4277-01)
4%, 5 mL preservative-free glass ampule, 25 count (NDC 00409-4283-01)

Estimated Resupply Dates

  • AuroMedics has 1% lidocaine 2 mL vials on intermittent back order and the company is releasing product as it becomes available. AuroMedics has 2% lidocaine 2 mL and 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Fresenius Kabi has 1% lidocaine 2 mL and 10 mL vials on back order and the company estimates a release date of mid-October 2016 for the 2 mL vials and late-September for the 10 mL vials. The 2% lidocaine 2 mL and 5 mL vials are on back order and the company estimates a release date of early-October 2016 for the 2 mL vials and mid-September 2016 for the 5 mL vials. The 1% Xylocaine 20 mL and 50 mL vials are on intermittent back order and the company is releasing product as it becomes available. The 2% Xylocaine 20 mL and 50 mL vials are on intermittent back order and the company is releasing product as it becomes available.
  • Hospira has 1% lidocaine 30 mL vials, preservative free, in sterile pack on back order and the company cannot estimate a release date. The 2% lidocaine 50 mL vials are available in limited supply.

Related Shortages

Updated

September 9, August 11, July 13, May 16, April 28 and 6, March 30, 22, 11 and 4, February 25, January 14, 13 and 6, 2016; December 17 and 3, November 12, October 19 and 12, September 25 and 10, August 25, June 23, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing